In the first strategy, we observed remarkably reduced AML burden as assessed by the frequency of GFP+ AML cells and by white blood cell (WBC) counts and smaller size of spleen in the Brd9 KO background compared to control (Fig. 7b and Supplementary Fig. 12a). This evidence concerns the gene BRD9 and acute myeloid leukemia.